No Data
Jefferies Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $51
Hold Rating on Bristol-Myers Squibb Amid Asundexian Trial Uncertainties and Milvexian Prospects
US Will Still Pay at Least Twice as Much After Negotiating Drug Prices
Reported Earlier, Bristol Myers Squibb Presents 3.5-Year Data on CAMZYOS at ESC 2024
Barclays Maintains Bristol-Myers Squibb(BMY.US) With Sell Rating, Maintains Target Price $42
Barclays Keeps Their Sell Rating on Bristol-Myers Squibb (BMY)
RDK79 : Sorry, what’s a pdufa?
Xyno RDK79 : Prescription Drug User Fee Act, means FDA approval or rejection for a drug to go to market. One of the most important events to monitor if you are into pharma companies stock.
RDK79 Xyno : Thank you!
Tonyco : What site is that?